Best of the Week
Most Popular
1. US Housing Market Real Estate Crash The Next Shoe To Drop – Part II - Chris_Vermeulen
2.The Coronavirus Greatest Economic Depression in History? - Nadeem_Walayat
3.US Real Estate Housing Market Crash Is The Next Shoe To Drop - Chris_Vermeulen
4.Coronavirus Stock Market Trend Implications and AI Mega-trend Stocks Buying Levels - Nadeem_Walayat
5. Are Coronavirus Death Statistics Exaggerated? Worse than Seasonal Flu or Not?- Nadeem_Walayat
6.Coronavirus Stock Market Trend Implications, Global Recession and AI Stocks Buying Levels - Nadeem_Walayat
7.US Fourth Turning Accelerating Towards Debt Climax - James_Quinn
8.Dow Stock Market Trend Analysis and Forecast - Nadeem_Walayat
9.Britain's FAKE Coronavirus Death Statistics Exposed - Nadeem_Walayat
10.Commodity Markets Crash Catastrophe Charts - Rambus_Chartology
Last 7 days
The Beatings Will Continue Until the Economy Improves - 6th Jul 20
The Corona Economic Depression Is Here - 6th Jul 20
Stock Market Short-term Peaking - 6th Jul 20
Gold’s Major Reversal to Create the “Handle” - 5th July 20
Gold Market Manipulation And The Federal Reserve - 5th July 20
Overclockers UK Custom Build PC Review - 1. Ordering / Stock Issues - 5th July 20
How to Bond With Your Budgie / Parakeet With Morning Song and Dance - 5th July 20
Silver Price Trend Forecast Summer 2020 - 3rd Jul 20
Silver Market Is at a Critical Juncture - 3rd Jul 20
Gold Stocks Breakout Not Confirmed Yet - 3rd Jul 20
Coronavirus Strikes Back. But Force Is Strong With Gold - 3rd Jul 20
Stock Market Russell 2000 Gaps Present Real Targets - 3rd Jul 20
Johnson & Johnson (JNJ) Big Pharma Stock for Machine Learning Life Extension Investing - 2nd Jul 20
All Eyes on Markets to Get a Refreshed Outlook - 2nd Jul 20
The Darkening Clouds on the Stock Market S&P 500 Horizon - 2nd Jul 20
US Fourth Turning Reaches Boiling Point as America Bends its Knee - 2nd Jul 20
After 2nd Quarter Economic Carnage, the Quest for Philippine Recovery - 2nd Jul 20
Gold Completes Another Washout Rotation – Here We Go - 2nd Jul 20
Roosevelt 2.0 and ‘here, hold my beer' - 2nd Jul 20
U.S. Dollar: When Almost Everyone Is Bearish... - 1st Jul 20
Politicians Prepare New Money Drops as US Dollar Weakens - 1st Jul 20
Gold Stocks Still Undervalued - 1st Jul 20
High Premiums in Physical Gold Market: Scam or Supply Crisis? - 1st Jul 20
US Stock Markets Enter Parabolic Price Move - 1st Jul 20
In The Year 2025 If Fiat Currency Can Survive - 30th Jun 20
Gold Likes the IMF Predicting a Deeper Recession - 30th Jun 20
Silver Is Still Cheap For Now - 30th Jun 20
More Stock Market Selling Ahead - 30th Jun 20
Trending Ecommerce Sites in 2020 - 30th Jun 20
Stock Market S&P 500 Approaching the Precipice - 29th Jun 20
APPLE Tech Stock for Investing to Profit from the Machine Learning Mega trend - 29th Jun 20
Student / Gamer Custom System Build June 2020 Proving Impossible - Overclockers UK - 29th Jun 20
US Dollar with Ney and Gann Angles - 29th Jun 20
Europe's Banking Sector: When (and Why) the Rout Really Began - 29th Jun 20
Will People Accept Rampant Inflation? Hell, No! - 29th Jun 20
Gold & Silver Begin The Move To New All-Time Highs - 29th Jun 20
US Stock Market Enters Parabolic Price Move – Be Prepared - 29th Jun 20
Meet BlackRock, the New Great Vampire Squid - 28th Jun 20
Stock Market S&P 500 Approaching a Defining Moment - 28th Jun 20
U.S. Long Bond: Let's Review the "Upward Point of Exhaustion" - 27th Jun 20
Gold, Copper and Silver are Must-own Metals - 27th Jun 20
Why People Have Always Held Gold - 27th Jun 20
Crude Oil Price Meets Key Resistance - 27th Jun 20
INTEL x86 Chip Giant Stock Targets Artificial Intelligence and Quantum Computing for 2020's Growth - 25th Jun 20
Gold’s Long-term Turning Point is Here - 25th Jun 20
Hainan’s ASEAN Future and Dark Clouds Over Hong Kong - 25th Jun 20
Silver Price Trend Analysis - 24th Jun 20
A Stealth Stocks Double Dip or Bear Market Has Started - 24th Jun 20
Trillion-dollar US infrastructure plan will draw in plenty of metal - 24th Jun 20
WARNING: The U.S. Banking System ISN’T as Strong as Advertised - 24th Jun 20
All That Glitters When the World Jitters is Probably Gold - 24th Jun 20
Making Sense of Crude Oil Price Narrow Trading Range - 23rd Jun 20
Elon Musk Mocks Nikola Motors as “Dumb.” Is He Right? - 23rd Jun 20
MICROSOFT Transforming from PC Software to Cloud Services AI, Deep Learning Giant - 23rd Jun 20
Stock Market Decline Resumes - 22nd Jun 20
Excellent Silver Seasonal Buying Opportunity Lies Directly Ahead - 22nd Jun 20
Where is the US Dollar trend headed ? - 22nd Jun 20
Most Shoppers have Stopped Following Supermarket Arrows, is Coughing the New Racism? - 22nd Jun 20

Market Oracle FREE Newsletter

AI Stocks 2020-2035 15 Year Trend Forecast

Best Investor Play in the Hottest Biotech Stock Market on Earth

Companies / Tech Stocks Jun 17, 2015 - 08:01 AM GMT

By: ...

Companies Michael A. Robinson writes: Biotechnology is a big opportunity. And China is a big market.

Combine the two and you have a big potential for investment profits.

In today’s Strategic Tech Investor, I’m talking with Money Map Press Executive Editor William Patalon III, who also heads up the Private Briefing service, about a big profit play in the Chinese biotech market.

It’s a brand-new recommendation…

The Best Chinese Biotech Play

Bill Patalon: Michael, you and I both like the long-term potential of the “right” China-focused investments. And we‘re both big believers in the long-term upside for the biotech sector. You’ve told me about a stock that offers a “double-barreled” return by focusing on both of these opportunity/catalyst areas – China Biologic Products Inc. (NASDAQ: CBPO).

Let‘s start by telling folks what is it about biotech, and about China, that you like?

Michael Robinson: Well, Bill, I know that you – like me – have been following biotech for a long time. In fact, I believe you had the biotech beat at The Baltimore Sun.

BP: (laughing) You have a good memory, Michael.

MR: Well, I’ve been following biotech since the early 1980s, and I can tell you this emphatically: We’ve now reached the point where many of the innovations and breakthroughs that were on the drawing boards for years are finally coming to fruition.

That’s why you see both small-cap and mega-cap biotech and Big Pharma companies coming out with so many new products over the past five years. And it’s why there are hundreds more in their pipelines.

More to the point, the United States has an aging population, meaning folks need those drugs to improve their health and extend their lifespans, which continue to rise.

BP: Then there’s China.

MR: That’s right, Bill. Then there’s China.

In China, we have a massive population of 1.3 billion people.

I mean, think about that.

BP: That’s more than four times the 2014 U.S. population of 318.9 million. And for some additional context, China’s middle class is bigger than the entire U.S. population.

MR: That’s right, Bill.

BP: In fact, by 2022, according to McKinsey Greater China, that Asian giant could have a middle class of 630 million people. And it’s all because of economic growth. That would represent 78% of all urban households, up from 68% in 2012 and 4% in 2000.

And those statistics show…

MR: … that there’s a huge customer base for biotech products. What’s more, Bill, is that Beijing is pushing a transformation from rural provinces to the big cities where incomes are rising and where residents can afford better healthcare.

BP: Okay, we’ve really described the lay of the land here. So let’s now move on and talk about China Biologic Products. What does it do? And why do you like it, as a business?

MR: Let’s boil this down…

At its core, China Biologic Products sells blood and related products. As such, it’s set to continue reaping the gains that comes with China’s mass urbanization trend – as well as the continued increase in disposable income and the Chinese people’s accompanying ability to spend more on healthcare.

BP: In essence, all the stuff that McKinsey was talking about…

MR: That’s exactly right.

This biosciences firm, based in Beijing, owns a pharmaceutical-distribution business, a research facility and 12 plasma-collection centers. It sells plasma directly to more than 1,000 hospitals across China. As those numbers steadily rise, so will the company’s revenue.

China’s plasma market used to be controlled by state-owned facilities run by the China National Blood Products Corp., provincial governments and the Chinese army. But in the past decade, officials opened the sector to private entrepreneurs who used cutting-edge technologies to create high-quality plasma products.

China Biologic was launched in 2002 as a privatized spinoff of the Shandong Institute, a research entity formerly run by the Shandong Provincial Health Department. It’s now the second-largest plasma collector in the country.

BP: Okay, we talked about the company. About the biotech sector. And about China, as a market and an economy. Now explain why you like the stock.

MR: It’s interesting, Bill, but as an investor, one thing that I realize is that – despite different languages, customs and geographic borders – people really don’t differ from one country to the next as much as we sometimes think.

BP: And by that you mean…

MR: Well, I think we’re all the same in that – at our core – we pretty much want the same things. I mean, we want the best for our families: good, safe food, effective healthcare to take care of our spouses and our children when they are sick.

And as incomes rise, and those goals become more attainable, people become less and less accepting of products that don’t measure up.

BP: Like some of the food-quality/food-safety issues we’ve seen in China over the past few years…

MR: Exactly, Bill.

And here’s another story that underscores this same basic consumer desire. It’s a story – a tragedy, really – that directly benefits China Biologic.

BP: You’re referring to the blood-supply issue you’ve told me about before.

MR: Right. In China, in the late 1980s and early ’90s, there was a real spread of HIV through that country’s rural regions – because of a contaminated blood supply. And that led to a government crackdown on plasma donations.

That, in turn, has crimped supplies at a time of rising demand. China’s government has set strict rules for plasma collection.

For China Biologic, and for investors, that continuing demand/supply imbalance has created a huge profit stream.

In fact, the numbers show that China Biologic is a wealth machine. It has operating margins of 45% and a 36% return on equity (ROE). Over the past three years, it’s grown its earnings per share (EPS) by an average of 24% and sales by an average of 13%.

I always like to find a stock that allows us to profit as the underlying company solves a problem for consumers.

BP: Interestingly, Zacks Equity Research just gave China Biologic its top (Strong Buy) ranking – meaning we‘re talking about a potential Zacks Effect”stock here.

MR: That’s an excellent point. The stock has mostly been in an uptrend over the past year, even though it doesn’t get a lot of attention from Wall Street at a time that has investors so worried about China’s growth.

Zacks is recommending the stock for many of the same reasons I like it. The company has great margins and high growth and has had a string of strong earnings reports.

Not only that, but Zacks has given China Biologic a $137 price target. If that’s all we get, we’re still talking a roughly 27% upside from here. Based on the firm’s earnings track record, I actually think we could see double those returns over the next two to three years.

BP: Anything we need to be concerned about here?

MR: There are two main risks I see with this stock. They’re interrelated and are tied to market conditions.

Let’s start with the macro view. Many pros on Wall Street are worried about investing in China now that economic growth there has slowed from the 10% pace of a few years back to the current 7% or so.

And it could slow more, meaning there’s always the risk that a couple of major Wall Street houses could go on a “Sell China” spree that will rattle investors. Fortunately, at this point, I think much of that is now priced into the market.

The second risk involves the market’s recent volatility. We’ve seen time and again during earnings season growth stocks that miss earnings by as little as a penny a share just get hammered.

BP: How would you structure the trade for this?

MR: I’d use my Cowboy Split strategy to both enter and exit this investment. While we were talking today [June 8], China Biologic came under heavy selling pressure on no news: The company has not issued a press release since May 6 when it reported strong earnings.

To take advantage of these kinds of buying opportunities, I’d likely make this a three-tiered entry. I’d start with one-third at market, the next third about 15% below that price and the final third about 15% below the average entry price.

And in this market, I advocate grabbing smaller gains along the way. So with China Biologic, I’d definitely be thinking about taking some money off the table when the stock is up 35% to 50%.

BP: Is there anything else you like that‘s poised to be a China beneficiary right now?

MR: Well, I put Alibaba Group Holding Ltd. (NYSE: BABA) in The Million Dollar Tech Portfolio for a reason. It’s on the path to become even bigger than Inc. (Nasdaq: AMZN).

Besides that e-commerce giant, there are three in particular that I think will do well in China’s current economic climate. Two are straight-up stock plays, and one is an ETF. All three have a tie to China’s burgeoning Web market.

I like Bitauto Holdings Ltd. (NYSE ADR: BITA) as a play on China’s huge auto industry, and NetEase Inc. (Nasdaq ADR: NTES) as a play on online gaming, and the Emerging Markets Internet & Ecommerce ETF (NYSE ARCA: EMQQ) to cover the waterfront of China’s online world.

BP: Like you, I’m a big believer in the e-commerce potential of China. But why do you like these three profit plays right now?

MR: Those stocks have gained. But don’t let that deter you. Think about all the growth that’s still to come in China.

Bitauto is the leading e-commerce player focused on the auto market, where we’re seeing a bit of a slowdown, but still about 18 million cars and light-duty trucks a year being sold. The company has a seat at both sides of the table. It helps buyers and sellers.

BP: And China’s auto market is now the world’s biggest…

MR: That’s correct. Bitauto’s shares sold off a few months back on a classic Wall Street overreaction. Since it bottomed out on March 16, it’s rallied for a 29% gain, and I see a lot more upside ahead. As you said, Bill, China is now the world’s largest car market and will benefit from the shift to big cities we talked about a moment ago.

BP: And NetEase?

MR: That’s one of China’s pioneering e-commerce companies. It’s still heavily focused on Web games and is a great way to play the nation’s gaming obsession. Forecasters at the Market Intelligence & Consulting Institute (MIC) project that China will pass the U.S. next year as the world’s largest online game market with a value of $22 billion.

BP: Okay, so take us through EMQQ.

MR: I like EMQQ as a very broad play on the China’s entire Internet industry. I know the fund manager personally, and he tells me the average stock in his portfolio is growing sales at 40% a year, or 20 times that of U.S. GDP growth.

BP: That’s off the charts.

MR: It is. It really is.

BP: How would you play those stocks – structure the trades?

MR: With EMQQ, I would play this as a straight-and-simple long-term foundational investment. In other words, this is one I’d be adding to over the long haul, putting in a set amount every year.

BP: Getting rich on “autopilot“?

MR: Exactly.

BP: And Bitauto and NetEase?

MR: With Bitauto and NetEase, I would play them pretty much the same as with China Biologic. I do like all three for the long haul, but these are growth stocks that could be subject to the market’s volatility. But with a tiered strategy, you can turn that to your advantage.

BP: Thanks, Michael.

P.S. If you like what Bill Patalon has to say and you’re interested in making a triple-digit return over the next 30 to 60 days, then there’s one company I want you to learn about. The events in Baltimore recently unleashed a new technology that will not only prevent destructive riots from happening again… but could also make a fortune for investors who seize this new opportunity. Bill just put the finishing touches on a special investor’s report on this company and its technology. Just click here to learn how to get it.

Source :

Money Morning/The Money Map Report

©2015 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email:

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules